@article{oai:repo.qst.go.jp:00047006,
 author = {Xie, Lin and Yui, Joji and Fujinaga, Masayuki and Hatori, Akiko and Yamasaki, Tomoteru and Kumata, Katsushi and Wakizaka, Hidekatsu and Furutsuka, Kenji and Takei, Makoto and Jin, Zhao-Hui and Furukawa, Takako and Kawamura, Kazunori and Zhang, Ming-Rong and 謝 琳 and 由井 譲二 and 藤永 雅之 and 羽鳥 晶子 and 山崎 友照 and 熊田 勝志 and 脇坂 秀克 and 古塚 賢士 and 武井 誠 and 金 朝暉 and 古川 高子 and 河村 和紀 and 張 明栄},
 issue = {8},
 journal = {International journal of cancer},
 month = {Mar},
 note = {Oncoimaging using positron emission tomography (PET) with a specific radioprobe would facilitate individualized cancer management. Evidence indicates that ectopically expressed metabotropic glutamate 1 (mGlu1) receptor independently induces melanocyte carcinogenesis, and it is therefore becoming an important target for personalized diagnosis and treatment strategies for melanomas. Here, we report the development of an oncoprotein-based PET imaging platform in melanomas for noninvasive visualization and quantification of mGlu1 with a novel mGlu1-specific radioprobe, 4-(18) F-fluoro-N-[4-[6-(isopropyl amino)pyrimidin-4-yl]-1,3-thiazol-2-yl]-N-methylbenzamide ((18) F-FITM). (18) F-FITM shows excellent pharmacokinetics, namely the dense and specific accumulation in mGlu1-positive melanomas versus mGlu1-negative hepatoma and normal tissues. Furthermore, the accumulation levels of radioactivity corresponded to the extent of tumor and to levels of mGlu1 protein expression in melanomas and melanoma metastasis. The (18) F-FITM PET imaging platform, as a noninvasive personalized diagnostic tool, is expected to open a new avenue for defining individualized therapeutic strategies, clinical trials, patient management and understanding mGlu1-triggered oncologic events in melanomas.},
 pages = {1852--1859},
 title = {Molecular imaging of ectopic metabotropic glutamate 1 receptor in melanoma with a positron emission tomography radioprobe (18) F-FITM.},
 volume = {135},
 year = {2014}
}